Kenvue Inc. Plans Quarterly Dividend of $0.20 (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) declared a quarterly dividend on Thursday, April 25th, Zacks reports. Shareholders of record on Wednesday, May 8th will be paid a dividend of 0.20 per share on Wednesday, May 22nd. This represents a $0.80 dividend on an annualized basis and a yield of 4.21%. The ex-dividend date of this dividend is Tuesday, May 7th.

Kenvue has a payout ratio of 64.5% meaning its dividend is sufficiently covered by earnings. Analysts expect Kenvue to earn $1.25 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 64.0%.

Kenvue Price Performance

Shares of Kenvue stock opened at $19.00 on Friday. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. The business’s 50-day moving average price is $19.84 and its 200-day moving average price is $20.14. Kenvue has a 12 month low of $17.82 and a 12 month high of $27.80.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.28 by $0.03. The firm had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. Kenvue’s revenue for the quarter was down 2.7% compared to the same quarter last year. Analysts expect that Kenvue will post 1.15 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on KVUE. JPMorgan Chase & Co. reduced their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. Royal Bank of Canada dropped their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. The Goldman Sachs Group began coverage on Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 target price for the company. William Blair began coverage on Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating for the company. Finally, Sanford C. Bernstein began coverage on Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.